Mutations in the PARN
PARN is a widely expressed cap-dependent poly(A) deadenylase with a canonical role in regulating global mRNA levels during development [3] [4] [5] [6] and additional, more specialized functions, including endtrimming of the Dicer-independent microRNA miR-451 (ref. 7) and deadenylation of small nucleolar RNAs (snoRNAs) 8 . PARN lossof-function mutations have recently been implicated in IPF 1 and dyskeratosis congenita 2 , but why a deficiency in PARN, which has no known role in telomere biology, should mimic telomere diseases is unexplained 9 .
TERC serves as the RNA template and scaffold for the telomerase reverse-transcriptase holoenzyme [10] [11] [12] , and its levels are tightly controlled, thereby limiting telomerase activity and telomere elongation in the cell 13, 14 . The TERC gene is amplified in several malignancies 15, 16 , whereas reduction in TERC levels due to genetic mutations in DKC1, NOP10, NHP2 or TERC itself results in telomere disease [17] [18] [19] [20] [21] . Because of its 3′ box H/ACA domain 22 , we hypothesized that TERC is regulated by PARN in a manner similar to that for other box H/ACA snoRNAs 8 . Here we show that cells from patients with PARN mutations manifest decreased levels of mature TERC RNA and increased levels of nascent transcripts with oligo(A) tails, which target nuclear RNAs for degradation 23, 24 . Our results demonstrate a critical role for PARN in TERC biogenesis and provide a mechanism by which PARN mutations cause telomere disease.
By candidate gene sequencing in subjects with genetically uncharacterized dyskeratosis congenita or telomere disease in the Pediatric Myelodysplastic Syndrome and Bone Marrow Failure Registry at Boston Children's Hospital, we identified biallelic defects in PARN in two families (Fig. 1a) , representing ~15% of the unrelated families in this disease category. The probands manifested classic features of dyskeratosis congenita and associated phenotypes, including bone marrow failure and very short telomere lengths in peripheral blood cells ( Fig. 1b and Supplementary Table 1 ). Patient 1 was found to carry an undescribed missense variant, c.19A>C, on the allele inherited from his mother, resulting in the substitution of a highly conserved amino acid, p.Asn7His, and a large deletion encompassing the entire PARN gene on the allele inherited from his father (Fig. 1c, Supplementary  Fig. 1 and Supplementary Table 2). Patient 2 was found to carry a heterozygous missense variant, c.260C>T, encoding the substitution of a highly conserved amino acid, p.Ser87Leu, inherited from his unaffected mother ( Supplementary Fig. 2a ,b and Supplementary Table 2 ). He and his affected brother had no other potentially pathogenic exon-encoded variants. However, for the proband, we found decreased levels of PARN mRNA transcripts from the 'normal' allele, indicating a noncoding defect on the allele inherited from his father ( Fig. 1d and Supplementary Fig. 2c ). In keeping with these findings, PARN mRNA levels were diminished in fibroblasts from both patients (Fig. 1e) , and PARN protein levels were even more severely compromised (Fig. 1f) . These data show compound heterozygous loss-of-function mutations in PARN in two families with dyskeratosis congenita and very short telomeres.
We found that fibroblasts from patients with PARN alterations had decreased steady-state levels of TERC (Fig. 2a) . Diminished TERC levels can result from disruption of dyskerin (encoded by DKC1), which binds and stabilizes TERC 18 , but cells from these patients did not carry mutations in DKC1 or demonstrate reductions in dyskerin protein levels (Fig. 1f) . To overcome limitations on cell numbers and study the effects of the PARN alterations in telomerase-expressing cells, we generated iPSCs from the fibroblasts of patients 1 and 2. These iPSCs also showed a deficiency in PARN transcripts and reduced TERC levels in comparison to normal iPSCs, without diminished dyskerin protein levels ( Fig. 2b-d) . We found that PARN-mutant iPSCs manifested decreased telomerase activity and impaired telomere elongation capacity in comparison to normal cells (Fig. 2e,f) but exhibit continuous self-renewal (with >25 passages thus far for all clones). To further investigate how PARN affects TERC levels, we knocked down PARN in HEK293 cells and again found reductions in TERC levels but not in the levels of DKC1 mRNA or dyskerin protein (Fig. 2g,h ). These studies demonstrate that PARN deficiency results in diminished TERC levels independently of DKC1 (dyskerin), as well as in deficits in telomerase activity and telomere maintenance.
Box H/ACA snoRNAs are encoded in introns and undergo maturation by exonucleolytic processing of spliced intermediates 25 . Nascent snoRNAs are subject to oligoadenylation by TRF4-2 (refs. 8, 26) , a component of the TRAMP (TRF4-2, AIR2, MTR4) complex, which stimulates degradation of nuclear RNAs by the exosome 27 . PARN counteracts snoRNA oligoadenylation and promotes 3′-end maturation, which may prevent further TRAMP-mediated oligo(A) addition and subsequent degradation 8 . TERC is transcribed by RNA polymerase II (Pol II) as an autonomous genetic unit. The transcript has a 7-methylguanosine cap and a precise 3′ end, but, unlike other Pol II-dependent transcripts, TERC RNA does not contain a long poly(A) tail, and the mechanisms of its 3′-end maturation are unknown 11, 22, 28, 29 . On the basis of the box H/ACA architecture shared by snoRNAs and TERC RNA and the recent finding that TERC exists in oligo(A)-containing forms 30 , we hypothesized that PARN participates in TERC 3′-end maturation and stabilization by removing oligo(A) tails from nascent transcripts.
We verified the presence of oligo(A)-containing forms of TERC by oligo(dT) 10 priming of total RNA for cDNA synthesis (Fig. 3a) and compared the relative proportions of oligo(A) and total TERC. We found a higher proportion of oligo(A) TERC in PARN-mutant fibroblasts and iPSCs than in normal cells (Fig. 3b) . Because TERC oligo(A) tails average 6-7 nt in length 30 and may not be quantified accurately using oligo(dT) 10 priming, we performed 3′ RACE analysis (Fig. 3c) . We observed an alteration in the size distribution of TERC 3′ ends in both patient-derived fibroblasts and iPSCs in comparison to normal cells, in that the intensity of the amplicon at the expected size was reduced and larger, extended transcripts predominated (Fig. 3d) . These results were recapitulated in HEK293 cells upon transient PARN knockdown (Fig. 3d) . By RNA blotting, using denaturing polyacrylamide gels, in vitro-transcribed TERC and endogenous mature TERC migrate as multiple bands 22 . In addition to these bands, we found more slowly migrating species in PARN-deficient cells, constituting a high proportion (~50%) of total TERC, in comparison to normal cells, and these species are likely to represent the extended TERC transcripts (Fig. 3e,f) . These data indicate that PARN deficiency results not only in diminished TERC steady-state levels but also in increased levels of TERC RNA species with abnormal 3′ ends.
To investigate this finding more closely, we profiled the 3′ ends of TERC RNA in fibroblasts and iPSCs by deep sequencing (Fig. 4) . We found a significant increase (P ≤ 0.05) in the proportion of TERC l e t t e r s npg l e t t e r s species other than mature TERC in patient-derived cells in comparison to normal cells, including transcripts extended beyond the canonical 3′ end and a diverse range of non-genomically encoded additions (Supplementary Fig. 3 ). We focused our attention on the distribution and frequency of two classes of TERC species: those containing up to eight genomically encoded bases beyond the canonical TERC end and the corresponding oligo(A) forms, which together comprised the majority of TERC forms across all samples. In patient-derived fibroblasts, we found that the percentage of mature TERC (ending at the canonical 5′-AUGC-3′ sequence) was markedly reduced in comparison to normal fibroblasts (59% versus 84%; Fig. 4a ). Because the total amount of TERC in patient-derived fibroblasts was ~45% of that in normal fibroblasts (Fig. 2a) , the level of mature TERC in patient-derived fibroblasts was approximately one-third that found in normal fibroblasts (27% versus 84%). At the same time, we found a significant increase in the proportion of oligo(A) forms of TERC, including transcripts with genomically encoded sequences beyond the 3′ end of mature TERC (Fig. 4a) . Haploinsufficiency due to deletion of one PARN allele in fibroblasts from the father of patient 1 yielded an intermediate phenotype ( Supplementary Fig. 4 ). In iPSCs, mature TERC comprised ~70% of all species in normal cells but only ~40% in patient-derived cells (Fig. 4b) . Again, we found significant increases in the proportion of oligo(A) forms of TERC transcripts extended beyond the 3′ terminus of mature TERC, with these transcripts, in aggregate, comprising the majority of the total TERC species in patient-derived iPSCs (Fig. 3b) . Next, we profiled HEK293 cells in which PARN had been disrupted by RNA interference and similarly found diminished levels of mature TERC and an increased proportion of oligo(A) TERC forms ( Supplementary Fig. 5 ). Sanger sequencing of 3′ RACE products corroborated the deep sequencing results (Supplementary Fig. 6 ). Consistently across all profiling experiments in patient-derived cells and cells with PARN knockdown, we observed a significant enrichment of oligo(A) forms of nascent TERC transcripts that were extended three, four or six bases beyond the canonical 3′ end. Collectively, the analyses performed in the setting of PARN deficiency show intermediates in TERC biogenesis Oligoadenylation is predicted to target nuclear RNAs for degradation, and we therefore determined the decay rate of TERC RNA in PARN-deficient versus normal cells. We inhibited Pol II transcription using actinomycin D and quantified TERC RNA levels by RNA blotting. We found a decreased half-life for TERC transcripts in patient-derived iPSCs in comparison to normal iPSCs and also in HEK293 cells with PARN knockdown in comparison to cells with control knockdown (Fig. 5) . These results indicate that PARN deficiency results in destabilization of TERC RNA and provide a mechanism for the observed decrease in steady-state TERC levels. (a) qPCR of TERC transcripts in cDNA from normal and patient-derived fibroblasts generated using random hexamer versus oligo(dT) 10 (a) Fibroblasts. 3′ RACE PCR products from normal and PARN-mutant patient-derived fibroblasts were subjected to deep sequencing, and reads were aligned to the TERC gene. The canonical TERC 3′ terminus is shown in red in the context of the TERC gene sequence. The relative proportions of mature TERC and TERC RNA species extending up to eight bases into the genomic sequence, with or without post-transcriptionally added oligo(A) tails, are depicted. Species with genomically encoded termini are in black, mature TERC with a single adenosine (which may be genomically encoded) is hatched and species with oligo(A) additions of any length (n) are in solid blue. Proportions are averaged for normal fibroblasts and patient-derived fibroblasts (n = 2 for each group). The total number of trimmed reads for each group is shown in parentheses. Error bars, s.d. For statistical evaluations, mature TERC forms and all genomically extended TERC species with oligo(A) n ends were compared between normal and patient-derived cells in a two-tailed t test. Significance is indicated: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; NS, not significant (black, mature TERC; blue, extended, oligo(A) n forms of TERC). (b) iPSCs. 3′ RACE PCR products from normal and PARN-mutant patient-derived iPSCs were subjected to deep sequencing, and reads were aligned to the TERC gene. Analyses and statistical comparisons were performed as in a. Proportions are averaged for normal iPSCs and patient-derived iPSCs (n = 2 for each group).
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Because the canonical role of PARN is believed to be in mRNA turnover, we performed RNA sequencing (RNA-seq) to assess the effects of PARN deficiency on mRNAs globally. Remarkably, we found that no protein-coding mRNAs manifested a fold change (increase or decrease) in steady-state levels that consistently exceeded the change in TERC levels in all seven sample pairs (Supplementary Tables 3  and 4) . These results suggest that the degree of PARN deficiency that is sufficient to disrupt TERC RNA transcript levels, 3′-end processing npg l e t t e r s and stability does not result in changes of a similar magnitude in the levels of mRNAs expressed across cell types. We next investigated the effects of ectopic PARN expression on TERC 3′-end processing. We used lentiviral vectors to overexpress PARN in HEK293 cells where PARN had been knocked down using a hairpin (shRNA 1) targeting the 3′ UTR (Supplementary Fig. 7) . We found not only rescue of the diminished steady-state levels of TERC (Fig. 6a) but also restoration of TERC processing, as evidenced by an increased proportion of 3′ RACE amplicons of the expected size relative to extended forms (Fig. 6b) . Similar results were obtained in patient-derived fibroblasts (Fig. 6c,d) . Deep sequencing confirmed an increased proportion of mature TERC (72% versus 45%) and a decreased proportion of oligo(A) TERC forms after PARN rescue in HEK293 cells (Fig. 6e) and partial restoration of 3′-end processing with ectopic PARN expression in patient-derived fibroblasts (Supplementary Fig. 8 ). We were unable to increase the levels of PARN protein in patient-derived iPSCs using lentivirus vectors, possibly because of silencing or toxicity (Supplementary Fig. 9) . Notably, when we overexpressed PARN in control HEK293 cells (Supplementary Fig. 7b ), we found a significant increase in the proportion of mature TERC (92% versus 75% in control cells) as well as a decrease in the proportion of extended species and oligo(A) forms (Fig. 6f) . Taken together, these studies demonstrate that the defects in TERC biogenesis in patients with PARN alterations can be restored by ectopic expression of PARN. Moreover, PARN appears to be limiting for TERC post-transcriptional processing and thus may have a pivotal role in determining telomerase levels in cells.
It is well established that the level of TERC in cells is important in health and disease 13 , including in tissue renewal [31] [32] [33] [34] [35] , degenerative disorders 20, [36] [37] [38] [39] [40] [41] , cancer 15, 16, 42 and possibly longevity 43, 44 , but the mechanisms by which TERC levels are regulated have remained elusive. Our findings, emerging from genetic discovery in patients with telomere diseases 1,2 , demonstrate that PARN mediates the posttranscriptional maturation of TERC. We propose that PARN removes oligo(A) tails and/or genomically encoded terminal nucleotides from nascent TERC transcripts, leading to maturation of the 3′ end and protection from further TRF4-2-mediated oligoadenylation and degradation by the exosome (Supplementary Fig. 10 ). We cannot exclude the possibility that PARN mutations contribute to disease manifestations by influencing the levels of other RNAs. However, given the phenotypic similarity of patients with PARN alterations and other forms of TERC deficiency, our results suggest that disrupting the role of PARN in TERC biogenesis may be sufficient to cause dyskeratosis congenita or telomere diseases. On the basis of our findings and those of others investigating the global effects of PARN disruption 8, 45 , we speculate that a major, non-redundant role of PARN in mammalian cells is not in mRNA metabolism but in regulating the biogenesis of TERC and other noncoding RNAs. Telomere length measurements. Flow-FISH. Telomere length in peripheral blood cell subsets was measured using flow-FISH 46 by Repeat Diagnostics.
Terminal restriction fragment length analysis. Genomic DNA (1.8 µg) was digested with the HinfI and RsaI restriction enzymes and separated on 0.8% agarose gels, followed by Southern blot analysis using the TeloTAGGG Telomere Length Assay kit (Roche).
Primary cells and cell lines.
Fibroblasts were cultured from skin biopsies obtained from patients and healthy volunteer subjects under approved protocols. Briefly, 2-mm punch biopsies were diced and placed under a coverslip in DMEM supplemented with 15% FCS until keratinocyte and fibroblast outgrowths were apparent. Fibroblasts were subcultured and expanded using 0.05% trypsin and DMEM supplemented with 15% FCS. The normal skin fibroblasts used in these experiments were from healthy adult volunteers and included NHSF2 (a gift from A. Klingelhutz, University of Iowa) and Hfib2 (ref. 47 ) cells. HEK293 and HEK293T cells (obtained from the American Type Culture Collection) were subcultured and expanded using 0.05% trypsin and DMEM supplemented with10% FCS. Derivation, characterization and culture of iPSCs from fibroblasts for patient 1 were performed as described 48 . NHSF2 cells and fibroblasts from patient 2 were reprogrammed using the pRRL.PPT. SF.hOKSMco.idTomato.preFRT lentiviral reprogramming vector 49 (a gift from A. Schambach, Hannover Medical School). WT1 iPSCs were derived from NHSF2 cells, and WT2 iPSCs were derived from hFib2 cells 47 . For feeder-free culture, iPSCs were maintained in Essential 8 medium (Life Technologies) on Matrigel matrix qualified for use with human embryonic stem cells (BD Biosciences). Cell lines were not tested for mycoplasma.
DNA sequencing and genetic analysis. DNA isolation and sequencing. Genomic DNA was extracted from primary cells and cell lines using the Gentra PureGene kit (Qiagen). DNA from research subject saliva samples was extracted with the prepIT kit (Oragene DNA Genotek). The primer sequences for PARN gene amplification and sequencing are provided in Supplementary  Table 5 . Sanger sequencing was performed by Genewiz.
Copy number determination by quantitative PCR. Copy number at the PARN locus in genomic DNA from fibroblasts, peripheral blood cells or saliva samples for family 1 was determined by performing qPCR using primers spanning PARN exon 1, PARN exon 24 and a control diploid locus (GPR15) (with PARNcopy_ex1L/R, PARNcopy_ex24L/R and GPR15copy_L/R primers, respectively; Supplementary Table 6). A standard curve was generated for each primer pair and used to calculate the relative copy number of each PARN amplicon, calibrated to GPR15 copy number. Quantitative measurements were normalized to those obtained with genomic DNA from a healthy volunteer.
Genome-wide SNP microarray analysis. Microarray analysis was performed on peripheral blood DNA from patient 1 using the Infinium Assay with the Illumina CytoSNP-850K BeadChip platform by the Cytogenetics program at Cincinnati Children's Hospital Medical Center.
RNA isolation, cDNA synthesis and quantitative RT-PCR. RNA from patient blood samples was processed using the PAXgene Blood RNA kit (Qiagen). RNA from cultured cells was recovered using TRIzol (Ambion). After DNase treatment (Turbo DNA-free, Ambion), cDNA was synthesized using 1 µg of total RNA, 50 ng of random hexamers or 7.5 ng of oligo(dT) 10 , and 1 µl of SuperScript III reverse transcriptase (Invitrogen) in a total volume of 20 µl for 1 h at 50 °C. qPCR was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) and the primers listed in Supplementary Table 6 (PARN_L/R, TERC_L1/R1, DKC1_L/R, POLR2A_L/R and ACTB_L/R) in a CFX96 Real-Time PCR detection system (Bio-Rad). PARN, TERC and DKC1 levels were normalized to those for POLR2A and/or ACTB, which in direct comparisons gave similar results. Graphing and statistical analysis of qPCR results were performed using GraphPad Prism. The sequences of the primers used for qPCR specific to the wild-type allele of the PARN gene in patient 2 (PARNcDNA_ex3L and PARNcDNA_ex5RWT) and for sequencing of PARN transcripts from peripheral blood cell cDNA from family 2 (PARNcDNA_ex4L and PARNcDNA_ex6R) are provided in Supplementary Table 6 .
To estimate the proportion of TERC that was oligoadenylated relative to total TERC (Fig. 3b) , standard curves were generated for TERC amplification using hexamer-primed cDNA and oligo(dT) 10 -primed cDNA, after normalizing to ACTB levels. Oligo(A) TERC levels were derived using oligo(dT) 10 -primed cDNA and represented as a percentage of total TERC levels, which were derived using hexamer-primed cDNA. The primers used were TERC_L/R and ACTB_L/R (Supplementary Table 6 ).
RNA blots. Agarose-formaldehyde gel electrophoresis. Total RNA (4-10 µg) was separated on 1.5% agarose-formaldehyde gels, transferred to HyBond N+ membranes (Amersham) in 10× SSC buffer by capillary transfer and hybridized with [α-32 P]dCTP-labeled full-length TERC probe in ULTRAhyb buffer (Life Technologies). Signals were normalized to 18S rRNA levels determined on the basis of ethidium bromide staining. Quantification was performed using ImageJ software.
Denaturing PAGE. Total RNA (1-2 µg) was separated on 5% polyacrylamide TBE-urea gels, transferred to HyBond N+ membranes by electroblotting and hybridized with [α-32 P]dCTP-labeled full-length TERC or U1 snRNA probe. In vitro-transcribed TERC RNA (20 pg) was loaded as a control. TERC signal was normalized to U1 snRNA signal. Quantification was performed using ImageJ software. The primers used to amplify the probes were TERC_L4 and TERC_R2 for TERC and U1snRNA_L and U1snRNA_R for U1 snRNA (Supplementary Table 6 ).
In vitro transcription of TERC RNA. The full-length TERC transcripts used for denaturing PAGE and RNA blots were generated by in vitro transcription using a T7 promoter-TERC PCR amplicon template (MAXIscript T7, Life Technologies). The primers used to generate the T7 promoter-TERC template were T7_TERC_L and TERC_R2 (Supplementary Table 6 ).
TERC RNA decay. iPSCs or HEK293 cells (0.5-1 × 10 6 ) were treated with 5 µg/ml actinomycin D (Life Technologies) and collected in TRIzol at 0, 1, 2 and 4 h after treatment. Purified RNA was subjected to RNA blotting by 1.5% agarose-formaldehyde gel electrophoresis, transfer to nylon membranes and hybridization as described above. TERC signal was normalized to 18S rRNA signal. The slopes for decay plots were determined by simple linear regression, and transcript half-life was calculated as the x intercept at y = 0.5, using GraphPad Prism.
Telomerase activity assays. iPSCs (2 × 10 5 ) were lysed in TRAPeze 1× CHAPS lysis buffer (Millipore), and protein was quantified by Bradford assay (Bio-Rad). Fivefold dilutions of cell extracts (containing 100 ng, 20 ng and 4 ng of protein) were subjected to the TRAP assays using the TRAPeze Telomerase Detection kit (Millipore). Products were resolved on 10% TBE polyacrylamide gels and visualized by staining with GelRed (Biotium). Table 6 ) and SuperScript III reverse transcriptase. PCR amplification was carried out using 5 µM of the TERC_L2 and universal RT or TERC_L3 and universal RT primer sets (Supplementary Table 6 ) with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad). PCR products were directly analyzed on 2.5% agarose gels to visualize mature TERC and extended TERC transcripts or subjected to QIAquick PCR purification columns (Qiagen) for library preparation for deep sequencing. For Sanger sequencing, 3′ RACE PCR products were directly cloned into the pCR4_TOPO vector (Life Technologies), and individual clones were sequenced using the TERC_L2 or TERC_L3 primer.
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MiSeq library preparation and analysis. RACE products were prepared for deep sequencing using the TruSeq Nano DNA LT Library Prep kit (Illumina). Briefly, for each sample, linkers carrying unique barcodes were ligated to the RACE products with DNA ligase. Ligated products were then amplified using primers containing Illumina adaptors and size selected using magnetic beads (AMPure). The completed libraries were submitted to the Tufts University Genomics Core for sequencing and data analysis. The quality and quantity of each library was determined on an Advanced Analytical Fragment Analyzer. The libraries were then pooled to equimolar concentrations. The pooled library was sequenced on an Illumina MiSeq instrument with paired-end 250-base reads using the Illumina TruSeq v2 500 Cycles kit. Reads were demultiplexed with CASAVA 1.8.2, and the read 1 and read 2 fastq files for each sample were generated. For data analysis, the Illumina adaptor sequence was first removed from the end of each read using Trimmomatic 50 . The resulting unbroken pair was then joined using FLASH 51 . Joined reads from each sample were mapped to the TERC gene (NR_001566) with the Bowtie 2 mapper 52 and outputted to a SAM file. The SAM file from each sample was then used as input for customdeveloped Perl scripts to remove the 3′ RACE universal adaptor sequence, determine the position at which the genomic sequence ended, and determine the position and length of the oligo(A) tail.
Code availability: The Perl scripts for TERC RNA end analysis will be made available upon request.
RNA-seq library preparation and analysis. RNA integrity was verified using the Advanced Analytical Fragment Analyzer. Total RNA (0.5-1 µg) was used as input for library preparation with the TruSeq Stranded Total RNA with RiboZero Gold kit (Illumina). The molar concentrations of the libraries were determined using the Advanced Analytical Fragment Analyzer, and the libraries were pooled at equimolar concentrations. The pooled libraries were sequenced on two lanes of a HiSeq 2500 instrument with High-Output singleread 50-base format. Sequence reads were aligned to the human transcriptome using HISAT version 0.1.6 (ref. 53) . The transcriptome file consisted of protein-coding and noncoding RNA sequences downloaded from Ensembl (release 80). To estimate transcript abundances, we applied Salmon version 0.3.2 (ref. 54 ) to the aligned reads and summarized transcript abundances into gene-level expression data by summing the expression levels for all transcripts mapping to the same gene. Gene-to-transcript mappings and transcript type annotations (for example, assignment of transcripts to categories such as snRNA, snoRNA, etc.) were also downloaded from Ensembl. Automated annotation was manually adjusted by annotating TERC and other small Cajal body-specific RNAs (scaRNAs) as snoRNAs for the purpose of this analysis.
We took two approaches to find genes that were commonly differentially expressed between normal and PARN-deficient cell lines. First, we performed the Wilcoxon signed-rank test on the 13,508 genes that had expression levels of at least 1 transcript per million (TPM) in one sample, using the following pairs of samples: WT1 fibroblasts versus patient 1 fibroblasts; WT1 IPSCs versus patient 1 clone 2 iPSCs; WT2 iPSCs versus patient 2 clone 1 iPSCs; and HEK293 cells with control knockdown versus HEK293 cells with PARN knockdown. No genes were differentially expressed with nominal significance (P ≤ 0.05) across all pairs using this approach or using the paired t test. Second, because we showed that TERC levels are decreased in PARN-deficient cell lines by qRT-PCR and RNA blotting, we reasoned that the magnitude of the fold change in its levels would be an appropriate threshold to define other genes as differentially expressed in paired comparisons. The comparison-specific thresholds in absolute values, which we refer to as TERC-defined thresholds, are provided in Supplementary Table 7 . We found that only one transcript, for a snoRNA (SCARNA13), showed a fold change in all seven comparisons that exceeded that for TERC (Supplementary Table 4) . We next lessened the stringency of our ad hoc metric of differential expression by allowing genes to be considered differentially expressed if they exceeded TERC-defined thresholds in fewer (five or six) than all seven pairwise comparisons. In this analysis, we asked whether the number of genes in each transcript category was different than would be expected by chance given the total number of genes differentially expressed, using the χ 2 test (Supplementary Table 3) .
Immunoblot analysis. Total cellular lysates were subjected to SDS-PAGE, and protein was transferred to PVDF membranes using standard procedures. Detection of PARN and dyskerin was performed using primary antibodies to human PARN (Abcam, ab188333; 1:5,000 dilution) and dyskerin (Santa Cruz Biotechnology, sc-48794; 1:1,000 dilution) and horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (Bio-Rad, 170-5046; 1:15,000 dilution), followed by chemiluminescent detection using Clarity Western ECL substrate (Bio-Rad). Protein loading was determined using HRP-conjugated antibody to actin (Santa Cruz Biotechnology, sc-1615; 1:1,000 dilution) on the same membranes and used for normalization. Imaging and quantification of chemiluminescent signals was performed using the Bio-Rad ChemiDoc Touch imaging system. Graphing and statistical analyses were performed using GraphPad Prism.
Lentiviral RNA interference and cDNA expression. shRNA constructs. Duplex oligonucleotides encoding shRNAs targeting human PARN (NM_002582) or luciferase control (Supplementary Table 6 ) were cloned into the pLKO.1-puro vector (Addgene, 10878), a gift from D. Root (Broad Institute).
cDNA expression constructs. cDNAs encoding the PARN ORF (NM_002582; bases 147-2066) or EGFP were PCR amplified and cloned into the BsrGI and AgeI sites of pLX301 (puromycin resistance; Addgene, 25895) and pLX304 (blasticidin resistance; Addgene, 25890), gifts from D. Root.
Lentiviral vector production and transduction. Lentiviral vectors encoding shRNAs or cDNAs were produced by cotransfection of HEK293T cells with the lentiviral plasmids described above, pCMV_dR8.91 and pCMV_VSV-G, using branched polyethylenimine (Sigma). Supernatants were collected, filtered and frozen in aliquots on day 3-4 after transfection. cDNA-expressing lentiviral vectors were concentrated by centrifugation. Titers, knockdown efficiency and cDNA expression were determined by infecting HEK293T cells for 16-24 h using varying quantities of viral supernatant in the presence of 10 µg/ml protamine sulfate. After 24-36 h, infected cells were selected with 2 µg/ml puromycin or 10 µg/ml blasticidin for 3-5 d, and RNA and/or protein were collected for analysis. For knockdown experiments, cells were transduced with lentivirus and collected 5-6 d after selection in puromycin (2 µg/ml for HEK293 cells, 1 µg/ml for fibroblasts and 0.2 µg/ml for iPSCs). For rescue experiments, control or knockdown cells that were selected for 5-6 d after transduction to express the shRNAs were infected with pLX304-based lentiviral vectors expressing PARN or EGFP and collected 4 d after selection in blasticidin (10 µg/ml for HEK293 cells and 5 µg/ml for fibroblasts).
